Decision-making strategies for optimal treatment of recurrent ovarian cancer (ROC) are complex as new cytotoxic drugs and an increasing number of biological agents become available. This presents challenges in defi ning the optimal timing and sequencing of the drugs or treatment regimen. A controversial issue of ROC treatment concerns the lack of an OS advantage observed with a number of investigational compounds and regimens, and they can be often associated with increased toxicity and no improvements in patients' QoL. Therefore, current treatment options for patients with ROC are frequently guided by safety considerations and convenience. A subanalysis of the OVA-301 study showed that for platinumsensitive patients (PFI >6 months), median progression-free survival was 9.2 months with the trabectedin + PLD combination vs 7.5 months with PLD monotherapy (hazard ratio, 0.73; 95% CI, 0.56 to 0.95; p=0.0170). In fact, the median overall survival in the patient subgroup with a platinum-free interval in excess of 12 months (considered to have very PS disease) was 36.5 months with the combination, which was in the range of that obtained with platinum combinations [1] .
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a b s t r a c t
Most patients with recurrent ovarian cancer (ROC) undergo a series of remissions and recurrences, therefore the additive or cumulative toxicity of chemotherapy must be factored into their treatment plan. There are challenges in defi ning tailored therapeutic approaches, including optimal timing and drug sequencing management strategies to treat patients with ROC. This is particularly relevant as new cytotoxic drugs and biological agents become available. Many of these drugs are associated with increased toxicity and with no observable survival advantage. Therefore current treatment options for the heavily-pretreated relapsing OC patient population are frequently guided by safety considerations and convenience. Rechallenge with platinum-based combination regimes is commonly limited by the risk of cumulative long-term toxicities. Not all patients can continue with platinum at secondline or, indeed, further relapses due to loss of activity or toxicity-related issues including hypersensitivity, neurotoxicity, alopecia and ototoxicity. In particular, hypersensitivity reactions are a concern and have been reported in approximately 15-20% of women receiving the drug. Trabectedin + PLD is a non-platinum combination that is well tolerated, with a manageable safety profi le, which is independent of age. of care for advanced ovarian cancer patients, the cumulative toxicities of cisplatin and carboplatin can present barriers for the long-term use of these agents [2, 3] . As previously discussed, there are women with relapsing disease (particularly the PPS subgroup) who would benefi t from a delay in platinum retreatment to possibly enhance their response to platinum in a future application, or who are not ideal candidates for platinumbased therapy due to the toxicity profi le of platinum or due to platinum-induced toxicity. There appear to be three main limitations to using carboplatin combinations, including allergy to carboplatin (hypersensitivity), renal toxicity, and ototoxicity. Hypersensitivity reactions (HSRs) to carboplatin are a particular concern, and have been reported in approximately 15-20% of women [2] . Symptoms of carboplatin HSRs are highly variable and can be mistakenly attributed to other agents, particularly when they are used in combination. They include itching, rash, chest tightness, emesis, blood pressure changes and facial swelling. The onset of the carboplatin-associated HSR is also highly variable, occurring either as soon as the infusion starts or after it is completed. When expectations for a positive outcome with platinum are good, then desensitisation protocols may be useful to continue platinumbased therapy, and success rates in excess of 50% have been reported [2] . However, for example a 12-step desensitization protocol that administers the total dosage of carboplatin at increasing doses and faster rates over an extended period of time, requires adequate support in an intensive care unit or allergy department. All with the attendant burden on staffi ng and resources, and of course patient preference [1, 2] .
Other clinically signifi cant sequelae such as neurotoxicity, severe cumulative myelosuppression, renal toxicity and ototoxicity are commonly caused by platinum-based chemotherapy. Indeed neurotoxicity, which infl uences patient's quality of life, is a dose-limiting adverse effect for all platinum compounds, and there is a high probability of persis tent neurotoxicity including residual neuropathy (~20% of OC patients) associated with carboplatin plus paclitaxel treatment [4] . Carboplatin causes dose-limiting and cumulative myelosuppression, characterised by frequent and severe thrombocytopenia, granulocytopenia and anaemia. Likewise, cisplatin is associated with several cumulative and irreversible toxicities, including dose-dependent renal tubule toxicity and neurotoxicity [5] . Cumulative doxorubicin and paclitaxel exposure must also be monitored to minimize the risk of patient morbidity due to cardiotoxicity and neuropathy. Gemcitabine has many overlapping toxicities with other agents, and care must be taken with combination regimens to avoid synergy of these adverse effects [3] .
Toxicity issues should be carefully taken into account before considering platinum re-treatment, as the platinumassociated cumulative and irreversible toxicities may jeopardise its long-term intervention on subsequent relapses. Consideration of platinum-induced cumulative toxicity takes on greater signifi cance as the number of salvage regimens increase, as it can be given only to those patients for whom the toxicities would be acceptable. This underscores the need for alternative therapeutic options, including an effi cacious non-platinum regimen with an acceptable toxicity profi le.
Other factors that infl uence treatment decisions in this heavily-treated patient population have to be taken into account. For example, effi cacy (clinical or symptom benefi t), safety (specifi cally limitations with carboplatin due to hyper sensitivity or residual toxicities) and QoL need to be considered. This could include health-related QoL, patientreported outcomes regarding symptoms, and time without symptoms or toxicity. For example, although temporary in nature, alopecia is a visible reminder of cancer treatment and is extremely upsetting for many women. A recent panEuropean survey into the QoL of 1743 patients with ovarian cancer by Oskay-Ozcelik et al. reported that alopecia was the single most troublesome side effect, with 42% patients reporting being bothered by alopecia [6] . It is known that platinum monotherapy and in combination with taxane does cause alopecia.
Furthermore, there is now an increasing body of evidence which shows that extending the platinum-free interval in relapsing patients with partially platinum sensitive ovarian cancer, also improves their response rate to platinum retreatment at a later time point [7] .
Trabectedin plus PLD is a non-platinum combination that is well tolerated with a manageable safety profi le
Clinical evidence from OVA-301 shows that the toxicity related to the trabectedin + PLD combination was acceptable. The most common adverse events with the trabectedin + PLD combination were neutropenia and transient increased transaminase levels (Box 1 and Table 1 ). The results show that neutropenia followed a predictable pattern of rapid onset and reversibility and, similarly, transaminase increases appear early after administration (during treatment cycles one and two), then generally decrease in incidence and severity with subsequent treatment cycles (Fig. 1) . Hence the clinician can assess the impact of the combination therapy on the patient from the fi rst 2 cycles.
The impact of trabectedin plus PLD combination on patients' QoL
The impact of the trabectedin + PLD combination was also assessed on patients' QoL via QLQ-C30, a standardised QoL instrument developed by the EORTC to assess the quality of life of cancer patients. Results from OVA-301 showed no difference in patients' QoL between the 2 study arms (Fig. 2) [10].
Conclusions
During the course of their illness, patients with ovarian cancer may undergo multiple cycles of treatment, with alternating multiple episodes of remission and relapse. Therefore ROC patients are treated over a continuum in which therapeutic choices and strategies may impact the effi cacy and safety of future therapies. Platinum rechallenge in combination or monotherapy regimes are often limited by hypersensitivity reactions and cumulative long-term toxicities, regardless of the regimen. Desensitisation protocols may be useful so as to allow treatment to continue, albeit with signifi cant burden on staffi ng and resources and with varying outcomes. The safety data from OVA-301 show that trabectedin + PLD can be considered as a treatment option at any relapse of ovarian cancer, including fully platinum-sensitive patients unsuited to receive subsequent platinum, with a manageable safety profi le and equivalent effi cacy. Therefore, trabectedin + PLD is a non-platinum alternative that is well tolerated. Furthermore, increasing evidence indicates that by extending the platinum-free interval with effective non-platinum agents such as trabectedin + PLD, patients are given some extra time to recover from any of the adverse effects of their prior platinum-based therapy with no detriment in QoL; and with even potential induction of their response to any subsequent platinum application, hence preserving their future treatment options.
Confl ict of Interest Statement
Professor Fotopoulou received speaker fees from PharmaMar for her participation at the BGCS 2014 symposium. Professor Fotopoulou is responsible for the content of this article. Patricia Howard Associates received fees from PharmaMar to provide editorial assistance.
r e f e r e n c e s
